<DOC>
	<DOCNO>NCT03056482</DOCNO>
	<brief_summary>Cannabis Hyperemesis Syndrome ( CHS ) become well-documented syndrome since 2004 expected increase prevalence continue liberalization marijuana recognition disease . Regardless whether association heavy cannabis use recognize , well-documented resistance traditional anti-emetic treatment . Given promise report use intravenous haloperidol , randomize control trial compare commonly administer anti-emetic ondansetron contribute management CHS</brief_summary>
	<brief_title>Haloperidol Versus Ondansetron Cannabis Hyperemesis Syndrome ( HaVOC )</brief_title>
	<detailed_description>This double-blinded , randomize , cross-over clinical trial enroll approximately 80 subject least four different research site . Patients diagnose CHS enrol study act control upon return ED subsequent bout CHS 3 visit per subject . Each patient allocate 1:1:1 fashion one three treatment group : high- low-dose haloperidol , ondansetron , minimum 7-day washout period treatment . As CHS tend recurrent syndrome ( presumably give continue use cannabis despite recommendation taper abstain ) , expect subject return least , substantial subset study population complete three treatment visit trial .</detailed_description>
	<mesh_term>Marijuana Abuse</mesh_term>
	<mesh_term>Hyperemesis Gravidarum</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<criteria>1 . Age &gt; 18 year 2 . Selfreport ≥3 episodes emesis occur cyclic pattern great 1 month precede 2 year 3 . Current episode &gt; 2 hour emesis 4 . At least one episode emesis/forceful retching witness ( include product emesis bedside ) heard independent observer ( healthcare provider family/friend ) emergency department 5 . Selfreported frequent ( near daily daily x least 6 month ) use cannabis inhalation . 6 . Working diagnosis cannabis hyperemesis syndrome opinion treat emergency physician 1 . Chronic , daily use opioid equivalent ≥10mg morphine/day 2 . Inability comprehend study consent instruction 3 . Unreliable followup/unlikely return crossover 4 . Administration intravenous antiemetic , anticholinergic antipsychotic ( 100mg dimenhydrinate ) previous 24 hour 5 . Allergy intolerance haloperidol ondansetron 6 . Pregnancy 7 . Any medical psychiatric condition opinion enrol physician would interfere participation trial 8 . Current active participation investigational drug trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>cannabis</keyword>
	<keyword>haloperidol</keyword>
	<keyword>ondansetron</keyword>
	<keyword>hyperemesis</keyword>
	<keyword>cyclic vomit syndrome</keyword>
</DOC>